FIELD: immunology and bioengineering.
SUBSTANCE: present invention refers to immunology and bioengineering. The variants of an antisubstance that is specific in relation to at least one globulomer Aβ(20-42) have been suggested. Each of the variants is characterized by the fact that it includes VH and VL parts; each of these parts contains three corresponding CDR. The antisubstance antigen-binding section has been revealed. They described: a coding nucleic acid and the vector that contains it, and a host cell that bears the vector that are used for the antisubstance production. The way of antisubstance production with the use of a cell has been discovered. The suggested inventions can find their application in therapy and diagnostics of Alzheimer's disease and other amyloid diseases.
EFFECT: antosubstances that can be used in therapy and diagnostics of Alzheimer's disease and other amyloid diseases.
10 cl, 28 dwg, 9 tbl, 12 ex
Title | Year | Author | Number |
---|---|---|---|
MONOCLONAL ANTIBODIES AND APPLICATIONS THEREOF | 2006 |
|
RU2432362C2 |
IMMUNOGENIC PRODUCTS OBTAINED BASED ON AMINO ACID SEQUENCES OF MUTEIN AMYLOID β (Aβ) AND THEIR APPLICATION METHODS | 2015 |
|
RU2750268C2 |
ADVANCED GLYCATION END PRODUCT (RAGE) RECEPTOR ANTIBODIES AND USING THEM | 2009 |
|
RU2518351C2 |
IMPROVED PROTOFIBRIL-SELECTIVE ANTIBODIES AND USE THEREOF | 2007 |
|
RU2429244C2 |
SAFE AND FUNCTIONAL HUMANIZED ANTIBODIES | 2011 |
|
RU2607368C2 |
Aβ-PEPTIDE ANTIBODIES AND APPLICATION THEREOF | 2003 |
|
RU2341533C2 |
BETA-AMYLOID ANTIBODIES | 2013 |
|
RU2689674C2 |
INTERLEUKIN-13 BINDING PROTEINS | 2007 |
|
RU2472807C2 |
HUMANIZED MONOCLONAL ANTIBODY AGAINST Aβ AND ITS USE | 2020 |
|
RU2783528C1 |
PROTOFIBRIL-BINDING ANTIBODIES AND USE THEREOF IN THERAPEUTIC AND DIAGNOSTIC METHODS FOR PARKINSON'S DISEASE, DEMENTIA WITH LEWY BODIES AND OTHER ALPHA-SYNUCLEINOPATHIES | 2011 |
|
RU2555526C2 |
Authors
Dates
2012-02-20—Published
2006-11-30—Filed